NL-OMON41310
Completed
Phase 3
High-dose baclofen for the treatment of alcohol addiction * A double-blind, randomized, placebo-controlled study - High-dose baclofen for the treatment of alcohol addiction
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- verslaving
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 130
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Male and Female patients, aged between 18\-70 years
- •\- Participants have a current DSM\-IV diagnosis of alcohol dependence
- •\- Participants sign a witnessed informed consent
- •\- Participants have a breath alcohol concentration lower than 0\.05 at the screening visit
- •\- Participants must have been drinking \* 14 drinks (female) or \* 21 drinks (males) on average per week over a consecutive 30\-day period in the 90\-day period prior to the start of the study and have two or more days of heavy drinking (5 drinks for females, 6 drinks for males) in the 90\-day period prior to the start of the study
- •\- Participants must have had a minimum of 96 hours of abstinence prior to the start of the medication
- •\- Participants can be abstinent for a maximum of 21 days prior to the start of the study
- •\- Participants must be able to speak and understand dutch
- •\- Participants provide an identified locator person that can be contacted during the study in the event of loss of contact
Exclusion Criteria
- •\- Participants with severe psychiatric disorders (schizophrenia, schizoaffective disorder, bulimia/anorexia, dementia, or ADHD requiring medication) except for depression, bipolar disorder and anxiety
- •\- Participants with serious medical illnesses (Parkinson\*s disease, gastric ulcer, duodenal ulcer, cerebrovascular disease, respiratory insufficiency, hepatic or renal insufficiency, and epilepsy)
- •\*\- Patients who are treated with anti\-hypertensiva
- •\- Participants who are at risk of suicide evaluated by the suicidality module of M.I.N.I.
- •\- Participants who have a cognitive impairment which is likely to interfere with the understanding of the study and its procedures
- •\- Participants with a diagnosis of dependence on any drugs except for nicotine, cannabis, alcohol and caffeine, if alcohol dependence doesn\*t represent the main addiction
- •\- Participants who are/or could be pregnant or nursing infants.
- •\- Participants who intend to engage in additional treatment for alcohol\-related problems (except for self\-help treatments which are not considered as formal treatment).
- •\- Participants with current or recent (3 month prior to the start of the study) treatment with anti\-craving medication (acamprosate, naltrexone, disulfiram, or topiramate)
- •\- Participants who have had more than seven days of inpatient treatment for substance use disorder in the 30 days prior to the start of the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
High-dose baclofen for the treatment of alcohol addictioEUCTR2011-004142-17-NLAcademic Medical Centrum250
Completed
Not Applicable
High-dose baclofen for the treatment of alcohol addiction.alcohol dependence (AD)NL-OMON22245Academisch Medisch Centrum (AMC)160
Active, not recruiting
Not Applicable
Baclofen for the Treatment of Alcohol Dependence - BACLADEUCTR2010-021861-62-DECharité - Universitätsmedizin Berlin
Not yet recruiting
Phase 3
Baclofen for Alcohol DependenceAlcohol DependenceMental Health - AddictionACTRN12606000100594Sydney South West Area Health Service42
Active, not recruiting
Phase 1
Baclofen in managing acute alcohol withdrawalAlcohol withdrawal syndromeTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2015-005286-24-BE